These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31909766)

  • 1. [A patient with subcutaneous, lymph node and bone lesions for breast cancer: a progressive response to metronomic oral vinorelbine and capecitabine.].
    Ghilardi M
    Recenti Prog Med; 2019 Dec; 110(12):27e-30e. PubMed ID: 31909766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A patient with subcutaneous, lymph node and bone lesions for breast cancer: a progressive response to metronomic oral vinorelbine and capecitabine.].
    Ghilardi M
    Recenti Prog Med; 2019 Oct; 110(10):490-493. PubMed ID: 31657815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial.
    Montagna E; Palazzo A; Maisonneuve P; Cancello G; Iorfida M; Sciandivasci A; Esposito A; Cardillo A; Mazza M; Munzone E; Lai A; Goldhirsch A; Colleoni M
    Cancer Lett; 2017 Aug; 400():276-281. PubMed ID: 28131905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
    Saridaki Z; Malamos N; Kourakos P; Polyzos A; Ardavanis A; Androulakis N; Kalbakis K; Vamvakas L; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):35-42. PubMed ID: 21590447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study.
    Cazzaniga ME; Cortesi L; Ferzi A; Scaltriti L; Cicchiello F; Ciccarese M; Della Torre S; Villa F; Giordano M; Verusio C; Nicolini M; Gambaro AR; Zanlorenzi L; Biraghi E; Legramandi L; Rulli E;
    Breast Cancer Res Treat; 2016 Dec; 160(3):501-509. PubMed ID: 27752847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99).
    Hess D; Koberle D; Thurlimann B; Pagani O; Schonenberger A; Mattmann S; Rochlitz C; Rauch D; Schuller JC; Ballabeni P; Ribi K;
    Oncology; 2007; 73(3-4):228-37. PubMed ID: 18424887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vinorelbine plus Capecitabine (Vinocap): a retrospective analysis in heavily pretreated HER2 negative metastatic breast cancer patients.
    Torres A; Ramdial JL; Aguirre LE; Mahtani R; Vogel CL
    Breast Cancer Res Treat; 2019 Jul; 176(2):253-260. PubMed ID: 30900138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial.
    Adamo B; Bellet M; Paré L; Pascual T; Vidal M; Pérez Fidalgo JA; Blanch S; Martinez N; Murillo L; Gómez-Pardo P; López-González A; Amillano K; Canes J; Galván P; González-Farré B; González X; Villagrasa P; Ciruelos E; Prat A
    Breast Cancer Res; 2019 Sep; 21(1):108. PubMed ID: 31533777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial.
    Li JW; Zuo WJ; Ivanova D; Jia XQ; Lei L; Liu GY
    Breast Cancer Res Treat; 2019 Jan; 173(2):407-415. PubMed ID: 30361875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of an all-oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes.
    Kellokumpu-Lehtinen PL; Sunela K; Lehtinen I; Joensuu H; Sjöström-Mattson J;
    Clin Breast Cancer; 2006 Dec; 7(5):401-5. PubMed ID: 17239265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer patients: VICTOR-1 study.
    Cazzaniga ME; Torri V; Riva F; Porcu L; Cicchiello F; Capici S; Cortinovis D; Digiacomo N; Bidoli P
    Tumori; 2017 Jan; 103(1):e4-e8. PubMed ID: 27647223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer.
    Onyenadum A; Gogas H; Markopoulos C; Bafaloukos D; Aravantinos G; Mantzourani M; Koutras A; Tzorakoelefterakis E; Xiros N; Makatsoris T; Fountzilas G; Kalofonos HP
    J Chemother; 2007 Oct; 19(5):582-9. PubMed ID: 18073159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On and off metronomic oral vinorelbine in elderly women with advanced breast cancer.
    De Iuliis F; Salerno G; Taglieri L; Lanza R; Scarpa S
    Tumori; 2015; 101(1):30-5. PubMed ID: 25702645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The NAME trial: a direct comparison of classical oral Navelbine versus Metronomic Navelbine in metastatic breast cancer.
    Langkjer ST; Kenholm J; Jensen JD; Wedervang K; Brixen AT; Grunnet M; Stenbygaard L; Gilje B; Danø H; Glavicic V; Jacobsen EH; Brems-Eskildsen AS; Kruse HL; Dongsgaard T; Neimann J; Geisler J
    Future Oncol; 2019 Aug; 15(22):2561-2569. PubMed ID: 31215242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metronomic vinorelbine plus bevacizumab as salvage therapy for patients with metastatic breast cancer.
    Saloustros E; Kalbakis K; Vardakis N; Kalykaki A; Milaki G; Rovithi M; Agelaki S; Saridaki Z; Georgoulias V; Mavroudis D
    J BUON; 2011; 16(2):215-8. PubMed ID: 21766488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study.
    Steger GG; Dominguez A; Dobrovolskaya N; Giotta F; Tubiana-Mathieu N; Pecherstorfer M; Ardizzoia A; Blasinska-Morawiec M; Espinosa E; Villanova G
    Clin Breast Cancer; 2018 Feb; 18(1):e41-e47. PubMed ID: 28666812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer.
    Welt A; von Minckwitz G; Oberhoff C; Borquez D; Schleucher R; Loibl S; Harstrick A; Kaufmann M; Seeber S; Vanhoefer U
    Ann Oncol; 2005 Jan; 16(1):64-9. PubMed ID: 15598940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients.
    Montagna E; Pagan E; Cancello G; Sangalli C; Bagnardi V; Munzone E; Salè EO; Malengo D; Cazzaniga ME; Negri M; Peruzzotti G; Veronesi P; Viale G; Colleoni M
    Anticancer Drugs; 2022 Jan; 33(1):e628-e634. PubMed ID: 34407044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer.
    Nolè F; Catania C; Sanna G; Imadalou K; Munzone E; Adamoli L; Longerey B; Blanchot G; Goldhirsch A
    Ann Oncol; 2006 Feb; 17(2):322-9. PubMed ID: 16303864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. All-oral (vinorelbin plus capecitabine) combination regimen might be preferable to oral vinoreline or weeky paclitaxel in estrogen receptor-positive, HER2-negative patients with visceral metastasis.
    Altundag K
    J BUON; 2019; 24(6):2578. PubMed ID: 31983138
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.